Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC

作者：Lianxi Song, Liang Zeng, Qinqin Xu, Yizhi Li, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Zhe Huang, Haoyue Qin, Huan Yan, Xing Zhang, Fang Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Juan Yu, Xue Yang, Yang Xia, Xiaorong Dong, Gao Zhang, Nong Yang, Yongchang Zhang · 发表于：iScience · 年份：2025 · DOI：10.1016/j.isci.2025.113211 · 被引用次数：3 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment

-mutant NSCLC, and suggest that LSM may help identify patients most likely to benefit from Chemo+ICI.